Is Candel Therapeutics Inc (CADL) overvalued? · $592.0M cap
Candel Therapeutics Inc (CADL) is a biotechnology company listed on NASDAQ.
This page asks whether Candel Therapeutics Inc (CADL) looks expensive on cached numbers — not a short thesis.
No cached income statement for CADL, so there is no earnings base to call rich or cheap.
CADL currently screens at market cap $592.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CADL 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CADL stock page for the full model, not this heading.
Not investment advice.